12:00 AM
 | 
Sep 14, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ACE-031: Phase I data

Data from a dose-escalation, Canadian Phase I trial in 48 healthy volunteers showed that single subcutaneous doses of 1 mg/kg and 3 mg/kg ACE-031 increased lean body mass at day 57...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >